Your session is about to expire
← Back to Search
Virus Therapy
Treatment arm for Color Blindness (Colourbridge Trial)
Phase 1 & 2
Waitlist Available
Led By Dominik Fischer, Prof.
Research Sponsored by STZ eyetrial
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 14 - day 365
Awards & highlights
Summary
The purpose of this study is to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.
Eligible Conditions
- Color Blindness
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 14 - day 365
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 14 - day 365
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety (AE). Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Secondary outcome measures
Efficacy measures. Number of Participants With improved Visual Function.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Waiting group ArmExperimental Treatment1 Intervention
Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
Group II: Treatment armExperimental Treatment1 Intervention
single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
Find a Location
Who is running the clinical trial?
STZ eyetrialLead Sponsor
4 Previous Clinical Trials
109 Total Patients Enrolled
University Hospital TuebingenOTHER
563 Previous Clinical Trials
335,533 Total Patients Enrolled
Ludwig-Maximilians - University of MunichOTHER
355 Previous Clinical Trials
178,611 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger